Publications by authors named "Brian Leyland-Jones"

100Publications

Attrition of Patients on a Precision Oncology Trial: Analysis of the I-PREDICT Experience.

Oncologist 2020 Sep 19. Epub 2020 Sep 19.

Moores Cancer Center, University of California, San Diego, La Jolla, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/onco.13532DOI Listing
September 2020

DNA derived from archival tumor specimens can be used for germline pharmacogenetic analyses.

Pharmacogenomics 2020 08 29;21(13):899-902. Epub 2020 Jul 29.

Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs-2020-0071DOI Listing
August 2020

Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.

JAMA Oncol 2020 Sep;6(9):1355-1362

Berry Consultants, LLC, Austin, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2020.2535DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378873PMC
September 2020

Dasatinib attenuates overexpression of Src signaling induced by the combination treatment of veliparib plus carboplatin in triple-negative breast cancer.

Cancer Chemother Pharmacol 2019 Dec 20;84(6):1241-1256. Epub 2019 Sep 20.

Avera Center for Precision Oncology, Avera Cancer Institute, Sioux Falls, 1000 E 23rd St., Sioux Falls, SD, 57105, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-019-03962-8DOI Listing
December 2019

Exploratory Analysis of Single-Gene Predictive Biomarkers in HERA DASL Cohort Reveals That C8A mRNA Expression Is Prognostic of Outcome and Predictive of Benefit of Trastuzumab.

JCO Precis Oncol 2018 1;2. Epub 2018 Nov 1.

, , , , , , , , and , Avera Cancer Institute, Sioux Falls, SD; , , , and , Frontier Science Foundation-Hellas; , University of Athens, Athens, Greece; , Scripps Florida, Jupiter, FL; , MTA-TTK Lendület Cancer Biomarker Research Group, Budapest, Hungary; and , Royal Marsden Hospital, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/PO.18.00016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446467PMC
November 2018

Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing.

J Clin Oncol 2018 Oct 19:JCO1800328. Epub 2018 Oct 19.

Thomas P. Slavin, Kar Wing Kevin Tsang, Susan L. Neuhausen, Stacy W. Gray, and Jeffrey N. Weitzel, City of Hope, Duarte; Kimberly C. Banks, Darya Chudova, Justin I. Odegaard, Rebecca J. Nagy, Christine E. Lee, and Richard B. Lanman, Guardant Health, Redwood City; Razelle Kurzrock, University of California, San Diego, Moores Cancer Center, San Diego, CA; Geoffrey R. Oxnard, Dana-Farber Cancer Institute; Aditya Bardia, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA; Massimo Cristofanilli, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Angel A. Rodriguez, Houston Methodist Hospital; Funda Meric-Bernstam, The University of Texas MD Anderson Cancer Center, Houston, TX; Brian Leyland-Jones, Avera Cancer Institute, Sioux Falls, SD; Mike F. Janicek, Arizona Oncology Associates Gynecology Oncology, Scottsdale, AZ; Michael Lilly, Medical University of South Carolina, Charleston, SC; and Guru Sonpavde, The University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.00328
Publisher Site
http://dx.doi.org/10.1200/JCO.18.00328DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286162PMC
October 2018

Promise of Precision Medicine in Cancers: Lessons Learned.

S D Med 2017 Nov;70(11):486-490

Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, South Dakota.

View Article

Download full-text PDF

Source
November 2017

High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers.

JCO Precis Oncol 2017 13;1. Epub 2017 Oct 13.

, , , , , , , and , Avera Cancer Institute, Sioux Falls, SD; , , , , , and , Dana-Farber Cancer Institute, Boston, MA; , Children's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX; , Molecular Core, Scripps Florida, Jupiter, FL; , International Breast Cancer Study Group, Bern, Switzerland; , Montefiore Medical Center, Bronx, NY; , Fox Chase Cancer Center, Philadelphia, PA; , Breast Cancer Translational Research Laboratory/Institut Jules Bordet, Brussels, Belgium; , Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; and and , European Institute of Oncology, University of Milan, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/PO.17.00009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446538PMC
October 2017

Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary.

Cancer Res 2017 08 22;77(16):4238-4246. Epub 2017 Jun 22.

Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center, La Jolla, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-17-0628DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729906PMC
August 2017

Down's Syndrome and Triple Negative Breast Cancer: A Rare Occurrence of Distinctive Clinical Relationship.

Int J Mol Sci 2017 Jun 7;18(6). Epub 2017 Jun 7.

Center for Precision Oncology, Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, SD 57105, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms18061218DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486041PMC
June 2017

Mutation matters in precision medicine: A future to believe in.

Cancer Treat Rev 2017 Apr 16;55:136-149. Epub 2017 Mar 16.

Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, SD, USA; Department of Internal Medicine, SSOM, University of South Dakota, SD, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2017.03.002DOI Listing
April 2017

PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials.

Pharmacol Ther 2017 Jul 16;175:91-106. Epub 2017 Feb 16.

Genomic Oncology Institute, Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, SD, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pharmthera.2017.02.037DOI Listing
July 2017

Reply to T. Hasegawa et al and I. Gross et al.

J Clin Oncol 2016 11;34(31):3820-3821

Brian Leyland-Jones, Avera Cancer Institute, Sioux Falls, SD; Els Vercammen and Liang Xiu, Janssen Research & Development, Raritan, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.7681DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477934PMC
November 2016

Dual Blockade of HER-2 Provides a Greater Magnitude of Benefit in Patients With Hormone-Negative Versus Hormone-Positive Breast Cancer.

Clin Breast Cancer 2016 12 14;16(6):444-455. Epub 2016 Jun 14.

Avera Cancer Institute, Sioux Falls, SD. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2016.06.004DOI Listing
December 2016

Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers.

Oncotarget 2016 Jul;7(28):43124-43149

Department of Molecular & Experimental Medicine, Avera Research Institute, Sioux Falls, SD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.8988DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5190013PMC
July 2016

Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis.

JAMA Oncol 2016 Nov;2(11):1452-1459

Center for Personalized Cancer Therapy, Division of Hematology and Oncology, University of California, San Diego3Worldwide Innovative Network for Personalized Cancer Therapy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2016.2129DOI Listing
November 2016

Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers.

Am J Cancer Res 2016 15;6(4):714-46. Epub 2016 Mar 15.

Genomic Oncology, Avera Cancer InstituteSioux Falls, SD; Departmental of Internal Medicine, University of South DakotaSioux Falls, SD.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859880PMC
May 2016

Single Gene Prognostic Biomarkers in Ovarian Cancer: A Meta-Analysis.

PLoS One 2016 17;11(2):e0149183. Epub 2016 Feb 17.

Dept. of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, SD, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0149183PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4757072PMC
August 2016

A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy.

J Clin Oncol 2016 04 8;34(11):1197-207. Epub 2016 Feb 8.

Brian Leyland-Jones, Avera Cancer Institute, Sioux Falls, SD; Igor Bondarenko, Dnepropetrovsk Medical Academy; and Iryna Litvin, Dnepropetrovsk Regional Oncological Dispensary, Dnepropetrovsk; Vitaliy Smirnov, Donetsk Regional Anticancer Center, Donetsk; Oksana Tarasova, Institute of Medical Radiology, Kharkiv; Yaroslav Sparyk, Lviv State Oncology Regional Treatment and Diagnostic Centre, Lviv; and Sergey Polenkov, Chernigov Regional Oncology Center, Chernigov, Ukraine; Gia Nemsadze, Institute of Clinical Oncology (LTD. K. Madichi Mammological Center); Irakli Kokhreidze, Martin D. Abeloff Laboratory Cancer Research Center; Lia Abshilava, Chemotherapy and Immunotherapy Clinic Medulla; Mikheil Janjalia, Tbilisi Cancer Center; and Beka Samkharadze, Research Institute of Clinical Medicine, Tbilisi, Georgia; Rubi Li, St. Luke's Medical Center, Quezon City, Philippines; Kuntegowda C. Lakshmaiah, Kidwai Memorial Institute of Oncology, Bangalore; and Ranjan Kumar Mohapatra, Apollo Specialty Hospital, Chennai, India; Vladimir Vladimirov, Pyatigorsk Oncology Dispensary, Pyatigorsk, Russian Federation; and Liang Xiu, Eugene Zhu, Bruce Kimelblatt, Kris Deprince, Ilya Safonov, Peter Bowers, and Els Vercammen, Janssen Research & Development, Raritan, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.63.5649DOI Listing
April 2016

Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors.

Am J Transl Res 2015 15;7(10):1675-98. Epub 2015 Oct 15.

Department of Molecular & Experimental Medicine, Precision Oncology Center, Avera Research Institute Sioux Falls, SD, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4656750PMC
December 2015

The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.

JAMA Oncol 2016 Feb;2(2):217-24

Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium2Medical Oncology Clinic, Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2015.4377DOI Listing
February 2016

Role of "oncogenic nexus" of CIP2A in breast oncogenesis: how does it work?

Am J Cancer Res 2015 15;5(9):2872-91. Epub 2015 Aug 15.

Department of Molecular & Experimental Medicine, Avera Research Institute Sioux Falls, SD, USA ; Department of Internal Medicine, SSOM, USD Sioux Falls, SD, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633914PMC
November 2015

Re: Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.

J Natl Cancer Inst 2015 May 26;107(5). Epub 2015 Mar 26.

Internal Medicine and Pharmacology, University of Michigan Medical School, Ann Arbor, MI (JMR); Edith Sanford Breast Cancer Research, Sanford Health and Research, Sioux Falls, SD (BLJ); Department of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA (MR); Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX (AMT).

View Article

Download full-text PDF

Source
https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnc
Publisher Site
http://dx.doi.org/10.1093/jnci/djv065DOI Listing
May 2015

MYC-xing it up with PIK3CA mutation and resistance to PI3K inhibitors: summit of two giants in breast cancers.

Am J Cancer Res 2015 15;5(1):1-19. Epub 2014 Dec 15.

Department of Molecular & Experimental Medicine, Avera Research Institute Sioux Falls, SD ; Department of Internal Medicine, SSOM, University of South Dakota SD.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4300701PMC
January 2015

Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers.

Horm Cancer 2014 Dec 15;5(6):405-13. Epub 2014 Aug 15.

Department of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute, Dr. Molewaterplein 50, 3015 GE, Rotterdam, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12672-014-0196-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4228172PMC
December 2014

Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands.

Oncotarget 2014 Jul;5(13):4581-602

Department of Molecular and Experimental Medicine, Avera Research Institute, Sioux Falls, SD; Department of Internal Medicine, SSOM, University of South Dakota, Sioux Falls, SD.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4148086PMC
http://dx.doi.org/10.18632/oncotarget.2127DOI Listing
July 2014

Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).

J Clin Oncol 2014 Jul 9;32(20):2159-65. Epub 2014 Jun 9.

Evandro de Azambuja and Martine J. Piccart-Genhart, Institut Jules Bordet; Evandro de Azambuja, Breast European Adjuvant Study Team; Martine J. Piccart-Gebhart, Université Libre de Bruxelles, Brussels, Belgium; Marion J. Procter and Dominique Agbor-Tarh, Frontier Science Scotland, Kincraig, Kingussie; David A. Cameron, University of Edinburgh and Western General Hospital, Edinburgh; Ian E. Smith, Royal Marsden Hospital and the Institute of Cancer Research; Mitch Dowsett, the Royal Marsden National Health Service Trust, London, United Kingdom; Dirk J. van Veldhuisen, University of Groningen, Groningen, the Netherlands; Otto Metzger-Filho and Richard D. Gelber, Dana-Farber Cancer Institute, Boston, MA; Jutta Steinseifer, F. Hoffmann-La Roche, Basel; Thomas M. Suter, Swiss Cardiovascular Center, Inselspital, Bern University Hospital, Bern, Switzerland; Michael Untch, HELIOS Klinikum Berlin, Buch; Christian Jackisch, Klinikum Offenbach, Offenbach, Germany; Luca Gianni, San Raffaele Institute, Milan, Italy; Jose Baselga, Memorial Sloan Kettering Cancer Center, New York, NY; Richard Bell, Andrew Love Cancer Centre, Geelong Hospital, Geelong, Australia; and Brian Leyland-Jones, Edith Sanford Breast Cancer Research Institute, Sioux Falls, SD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.9288DOI Listing
July 2014

Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500.

J Clin Oncol 2014 Nov 2;32(31):3483-9. Epub 2014 Jun 2.

Jeffrey B. Smerage, Anne F. Schott, and Daniel F. Hayes, University of Michigan Comprehensive Cancer Center, Ann Arbor; Gordan Srkalovic, Sparrow Regional Cancer Center, Lansing; Sheela Tejwani, Henry Ford Hospital, Detroit, MI; William E. Barlow and Danika L. Lew, SWOG Statistical Center; Julie R. Gralow, Seattle Cancer Care Alliance, Seattle, WA; Gabriel N. Hortobagyi, University of Texas MD Anderson Cancer Center, Houston, TX; Eric P. Winer, Dana-Farber Cancer Institute, Boston, MA; Brian Leyland-Jones, Avera Cancer Institute, Sioux Falls, SD; Mark A. O'Rourke, Greenville Health System Cancer Institute/Greenville Community Clinical Oncology Program, Greenville, SC; Gerald V. Doyle, Immunicon, Huntingdon Valley, PA; and Robert B. Livingston, University of Arizona Cancer Center, Tucson, AZ.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2014/06/02/JCO.2014.56
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.56.2561
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.56.2561DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209100PMC
November 2014

Response.

J Natl Cancer Inst 2014 Apr 3;106(5). Epub 2014 Apr 3.

NotesAffiliations of authors: Department of Internal Medicine and Department of Pharmacology, Michigan Medical School, Ann Arbor, MI (JMR); Edith Sanford Breast Cancer Research, Sanford Health and Research, Sioux Falls, SD (BL-J); Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA (MR).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/dju064DOI Listing
April 2014

Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.

Neoplasia 2014 Jan;16(1):43-72

Department of Molecular and Experimental Medicine, Avera Cancer Institute, Sioux Falls, SD ; Department of Internal Medicine, University of South Dakota, Vermillion, SD.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3924548PMC
http://dx.doi.org/10.1593/neo.131694DOI Listing
January 2014

The safety of erythropoiesis-stimulating agents in cancer patients.

Clin Adv Hematol Oncol 2013 ;11(9):596-7

Director Edith Sanford Breast Cancer Research Sioux Falls, South Dakota.

View Article

Download full-text PDF

Source
October 2014

Differential activation of Wnt-β-catenin pathway in triple negative breast cancer increases MMP7 in a PTEN dependent manner.

PLoS One 2013 15;8(10):e77425. Epub 2013 Oct 15.

Edith Sanford Breast Cancer, Sanford Research, Sioux Falls, South Dakota, United States of America ; Internal Medicine, University of South Dakota, Sioux Falls, South Dakota, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0077425PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3797090PMC
June 2014

Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.

J Natl Cancer Inst 2013 Sep 19;105(17):1332-4. Epub 2013 Aug 19.

Breast Oncology Program, University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109-5942, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djt204DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888280PMC
September 2013

Erythropoiesis stimulating agents: a personal journey.

J Natl Cancer Inst 2013 Jul 16;105(14):999-1001. Epub 2013 Jul 16.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djt171DOI Listing
July 2013

Dissecting GRB7-mediated signals for proliferation and migration in HER2 overexpressing breast tumor cells: GTP-ase rules.

Am J Cancer Res 2013 3;3(2):173-95. Epub 2013 Apr 3.

Edith Sanford Breast Cancer Research, Sanford Research/USD Sioux Falls, SD.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3623837PMC
April 2013

Molecular determinants of trastuzumab efficacy: What is their clinical relevance?

Cancer Treat Rev 2013 Dec 3;39(8):925-34. Epub 2013 Apr 3.

Edith Sanford Breast Cancer Center, Sanford Research/USD, Sioux Falls, SD, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03057372130003
Publisher Site
http://dx.doi.org/10.1016/j.ctrv.2013.02.006DOI Listing
December 2013

Promise of rapalogues versus mTOR kinase inhibitors in subset specific breast cancer: old targets new hope.

Cancer Treat Rev 2013 Aug 23;39(5):403-12. Epub 2013 Jan 23.

Edith Sanford Breast Cancer, Sanford Research, 2301 E 60th Street N, Sioux Falls, SD 57104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2012.12.002DOI Listing
August 2013

Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls.

Lancet Oncol 2011 Mar;12(3):286-95

Emory Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(10)70297-7DOI Listing
March 2011

Hand-held spectroscopic device for in vivo and intraoperative tumor detection: contrast enhancement, detection sensitivity, and tissue penetration.

Anal Chem 2010 Nov 6;82(21):9058-65. Epub 2010 Oct 6.

Department of Biomedical Engineering and Chemistry, Emory University and Georgia Institute of Technology, 101 Woodruff Circle Suite 2007, Atlanta, Georgia 30322, United States, Division of Thoracic Surgery, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, United States, Departments of Biomedical Engineering, Oncology and Radiology, Emory University, 101 Woodruff Circle, Suite 2007, Atlanta, Georgia 30322, United States, Department of Radiology, Duke University Medical Center, Durham, North Carolina 27710, United States, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia 30322, United States, and Department of Biomedical Engineering, Georgia Institute of Technology, 313 Ferst Drive, UA Whitaker Building 4106, Atlanta, Georgia 30332, United States.

View Article

Download full-text PDF

Source
http://pubs.acs.org/doi/abs/10.1021/ac102058k
Publisher Site
http://dx.doi.org/10.1021/ac102058kDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3030682PMC
November 2010

Human epidermal growth factor receptor 2 testing: where are we?

J Clin Oncol 2010 Oct 9;28(28):4289-92. Epub 2010 Aug 9.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2010.29.5071DOI Listing
October 2010

Molecular mapping of tumor heterogeneity on clinical tissue specimens with multiplexed quantum dots.

ACS Nano 2010 May;4(5):2755-65

Department of Biomedical Engineering and Chemistry, Emory University and Georgia Institute of Technology, 101 Woodruff Circle Suite 2001, Atlanta, Georgia 30322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/nn100213vDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2923482PMC
May 2010

DNA extraction from formalin-fixed, paraffin-embedded tissue.

Cold Spring Harb Protoc 2009 Feb;2009(2):pdb.prot5138

Center for Medical Genomics, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1101/pdb.prot5138DOI Listing
February 2009

Whither HER2-related therapeutics?

J Clin Oncol 2010 Mar 1;28(7):1091-6. Epub 2010 Feb 1.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.25.8624DOI Listing
March 2010

Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated.

J Clin Oncol 2010 Feb 21;28(6):960-6. Epub 2009 Dec 21.

Winship Cancer Institute, Emory University, School of Medicine, 1365C Clifton Rd NE, Ste 4014, Atlanta, GA 30322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2009.23.1910DOI Listing
February 2010

Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases.

J Clin Oncol 2009 Nov 21;27(31):5278-86. Epub 2009 Sep 21.

Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, 30322, USA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2008.19.8481
Publisher Site
http://dx.doi.org/10.1200/JCO.2008.19.8481DOI Listing
November 2009

Pharmacology and pharmacogenetics of chemotherapeutic agents.

Cancer Invest 2009 Jun;27(5):482-8

Department of Oncology, Dubai Hospital, Dubai, United Arab Emirates.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/07357900802574660DOI Listing
June 2009

Predicting endocrine responsiveness: novel biomarkers on the horizon.

Oncology (Williston Park) 2009 Feb;23(2):154, 156, 159

Center for Medical Genomics, Winship Cancer Institute, Emory University, USA.

View Article

Download full-text PDF

Source
February 2009

Proteomics: new technologies and clinical applications.

Eur J Cancer 2008 Dec 1;44(18):2737-41. Epub 2008 Nov 1.

Faculty of Pharmacy, University of Montreal, Montreal, QC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2008.09.007DOI Listing
December 2008

Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models.

Growth Horm IGF Res 2008 Dec 23;18(6):487-96. Epub 2008 May 23.

Oncology Department, McGill University, Montreal, QC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ghir.2008.04.002DOI Listing
December 2008

Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.

Breast Cancer Res Treat 2009 Jan 7;113(2):357-70. Epub 2008 Mar 7.

Department of Epidemiology, Rollins School of Public Health, Emory University, 1518 Clifton Road, NE, Atlanta, GA 30322, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-008-9926-3DOI Listing
January 2009

Application of array-based genomic and epigenomic technologies to unraveling the heterogeneous nature of breast tumors: on the road to individualized treatment.

Cancer Genomics Proteomics 2007 May-Jun;4(3):135-45

VM Institute of Research, Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
November 2007

A systems approach to clinical oncology: focus on breast cancer.

Proteome Sci 2006 Apr 4;4. Epub 2006 Apr 4.

Center for Clinical Research in Oncology and Department of Oncology, McGill University, 546 Pine Avenue West, Montreal, Quebec, H2W 1S6, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1477-5956-4-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1456950PMC
April 2006

Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer.

Eur J Cancer 2005 Jul;41(11):1515-27

Laboratory of Molecular Pathology, Department of Anatomic Pathology and Division of Molecular and Cellular Biology, Sunnybrook and Women's College Health Sciences Centre, Toronto, Ont., Canada.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S095980490500350
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2005.04.023DOI Listing
July 2005

Treating cancer-related hypercalcemia with gallium nitrate.

J Support Oncol 2004 Nov-Dec;2(6):509-16

Department of Oncology, McGill University, 546 Pine Avenue West, Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
February 2005

Epoetin alfa: future directions and future research.

Oncologist 2004 ;9 Suppl 5:70-3

Department of Medicine and Medical Oncology, Wilhelminenspital, Montleartstrasse 37, A-1171 Vienna, Austria.

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theon
Publisher Site
http://dx.doi.org/10.1634/theoncologist.9-90005-70DOI Listing
March 2005

Optimizing treatment of HER2-positive metastatic breast cancer.

Semin Oncol 2004 Oct;31(5 Suppl 10):29-34

Royal Free Hospital, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2004.07.019DOI Listing
October 2004

Gene Expression Profiling of 2-(4-Aminophenyl)benzothiazole-resistant MCF-7 Cells Using cDNA Microarrays.

Cancer Genomics Proteomics 2004 May-Jun;1(3):215-224. Epub 2004 May 1.

Department of Oncology, McGill University, Montreal, QC, Canada.

View Article

Download full-text PDF

Source
May 2004

Anti-insulin-like growth factor strategies in breast cancer.

Semin Oncol 2004 Feb;31(1 Suppl 3):54-63

Department of Oncology, McGill University, Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2004.01.007DOI Listing
February 2004

Erythropoietin as a critical component of breast cancer therapy: survival, synergistic, and cognitive applications.

Semin Oncol 2003 Oct;30(5 Suppl 16):174-84

Department of Oncology, McGill University, Montreal, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2003.08.020DOI Listing
October 2003

Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel.

J Clin Oncol 2003 Nov 24;21(21):3965-71. Epub 2003 Sep 24.

Department of Oncology, McGill University, Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2003.12.109DOI Listing
November 2003